Linked Life Data

15951239

Source:http://linkedlifedata.com/resource/pubmed/id/15951239

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2005-7-6
pubmed:abstractText
Specifying the delivery of a highly toxic agent to cancers while sparing normal tissue is an attractive prospect for the treatment of cancer. Cell surface antigens with highly restricted expression patterns have been identified and the means by which cytotoxic agents are appended to antibodies has been greatly refined. Myriad formulations involving radionuclides, bacterial toxins and small-molecule drugs linked to antibodies through peptides, protein fusions and chelating agents are in preclinical and clinical evaluation, and a few have been approved as human medicines. Recent advances hold promise for improving the therapeutic index of these anti-cancer drugs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1471-4892
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
382-7
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Arming antibodies for cancer therapy.
pubmed:affiliation
Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA. ppolakis@gene.com
pubmed:publicationType
Journal Article, Review